MELVILLE, New York--Henry Schein, Inc. has announced that Henry Schein Dental and OraPharma, Inc., have entered into a relationship that will extend the offering of ARESTIN.
Through this agreement, Henry Schein Dental will serve as sales agent and exclusive U.S. distributor of ARESTIN, the first locally administered, time-released antibiotic encapsulated in microspheres that kills the germs that cause periodontal disease or periodontitis.
Henry Schein is a distributor of health-care products and services to office-based practitioners in the combined North American and European markets.
OraPharma is a Johnson Johnson company.
"This is an exciting alliance that provides Henry Schein Dental with a significant offering in an important new market for our Company," said Tim Sullivan, president of Henry Schein Dental. "Our goal is to provide 'everything dental' to our customers, and the addition of ARESTIN to our offering certainly furthers that mission. ARESTIN provides unique benefits for treating a condition that affects millions of Americans. We see great potential for the adoption of ARESTIN by our U.S. Dental customers, in addition to periodontists, and we look forward to collaborating with OraPharma's field representatives as we grow ARESTIN's market share in this country."
Currently, more than one in three Americans older than age 30 has some form of periodontal disease, according to the American Academy of Periodontology. Research shows that untreated periodontal infections may contribute to systemic health problems, including cardiovascular disease.
In addition, according to the Academy of General Dentistry, every $1 spent on preventative oral care results in an $8-$10 savings in subsequent restorative services.
For more information, visit the Henry Schein Web site at Henry Schein.
To read more about Henry Schein, go to Henry Schein.
To comment on this topic, go to PennWell Dental Community site.
